Parabilis Medicines (PBLS)
Develops Helicon peptides for hard-to-reach intracellular protein targets.
$40.61
Pre-market+0.57 (+1.42%)
At close$40.04(+1.44%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
123.53M company shares as of Sep 3, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P.incl. Peter Kolchinsky, Rajeev Shah +1 more | 23.80% | 28.93M | 13D | Jun 18, 2026 ↗ |
| ARCH Venture Fund XII, L.P. | 5.30% | 6.41M | 13G | Aug 14, 2026 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.